Emerging treatments for dry age-related macular degeneration with geographic atrophy: a systematic review
DOI:
https://doi.org/10.12809/hkjo-v25n2-315Keywords:
Cell- and tissue-based therapy, Complement inactivating agents, Dietary supplements, Geographic atrophy, Macular degenerationAbstract
We aim to summarize various emerging treatments for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The PubMed database was searched using keywords: 'treatment' and 'geographic atrophy' or 'dry age-related macular degeneration' on 19 June 2021. Of 121 articles yielded, 20 relevant clinical studies that were of 'English language' and 'published within 10 years' were included. The emerging treatments of dry AMD with GA were categorized into complement inhibitors, diet and supplement, cell-based therapies, and pharmacological agents. Complement inhibitors (C3 inhibitor pegcetacoplan, complement factor D, and C5 inhibitors) can significantly reduce the GA lesion area growth, as can Mediterranean diet and α-lipoic acid. Cell-based therapies such as palucorel and biosynthetic retinal pigment epithelium monolayer delivery can minimize GA lesion area and improve the best-corrected visual acuity. Pharmacological agents such as fenretinide, ciliary neurotrophic growth factor, trimetazidine, and brimonidine have prominent effects on GA, but emixustat hydrochloride, tandospirone, and sirolimus lack such effects. The Age-Related Eye Disease Study formulation remains important in reducing the risk of progression of GA secondary to dry AMD. A thorough understanding of the emerging treatment of GA may enable more personalized treatment. Nonetheless, the safety and efficacy of the treatment ought to be tested in trials with larger sample size, longer duration, and optimized dosage.
References
1. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet 2018;392:1147-59. DOI: https://doi.org/10.1016/S0140-6736(18)31550-2
2. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-43. DOI: https://doi.org/10.1016/S0161-6420(92)31871-8
3. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106-16. DOI: https://doi.org/10.1016/S2214-109X(13)70145-1
4. Mitchell P, Wang JJ, Foran S, Smith W. Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology 2002;109:1092-7. DOI: https://doi.org/10.1016/S0161-6420(02)01055-2
5. Ejiakor I, Achigbu E, Onyia O, Edema O, Florence UN. Impact of visual impairment and blindness on quality of life of patients in Owerri, Imo State, Nigeria. Middle East Afr J Ophthalmol 2019;26:127-32. DOI: https://doi.org/10.4103/meajo.MEAJO_256_18
6. Zajac-Pytrus HM, Pilecka A, Turno-Krecicka A, Adamiec-Mroczek J, Misiuk-Hojlo M. The dry form of age-related macular degeneration (AMD): the current concepts of pathogenesis and prospects for treatment. Adv Clin Exp Med 2015;24:1099-104. DOI: https://doi.org/10.17219/acem/27093
7. Arya M, Sabrosa AS, Duker JS, Waheed NK. Choriocapillaris changes in dry age-related macular degeneration and geographic atrophy: a review. Eye Vis (Lond) 2018;5:22. DOI: https://doi.org/10.1186/s40662-018-0118-x
8. Bandello F, Sacconi R, Querques L, Corbelli E, Cicinelli MV, Querques G. Recent advances in the management of dry age-related macular degeneration: a review. F1000Res 2017;6:245. DOI: https://doi.org/10.12688/f1000research.10664.1
9. Yehoshua Z, Rosenfeld PJ, Albini TA. Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures. Semin Ophthalmol 2011;26:167-80. DOI: https://doi.org/10.3109/08820538.2011.577132
10. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309:2005-15. DOI: https://doi.org/10.1001/jama.2013.4997
11. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-9. DOI: https://doi.org/10.1126/science.1109557
12. Vignesh P, Rawat A, Sharma M, Singh S. Complement in autoimmune diseases. Clin Chim Acta 2017;465:123-30. DOI: https://doi.org/10.1016/j.cca.2016.12.017
13. Anderson DH, Radeke MJ, Gallo NB, et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 2010;29:95-112. DOI: https://doi.org/10.1016/j.preteyeres.2009.11.003
14. Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology 2020;127:186-95. DOI: https://doi.org/10.1016/j.ophtha.2019.07.011
15. Volanakis JE, Narayana SV. Complement factor D, a novel serine protease. Protein Sci 1996;5:553-64. DOI: https://doi.org/10.1002/pro.5560050401
16. Yaspan BL, Williams DF, Holz FG, et al. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci Transl Med 2017;9:eaaf1443. DOI: https://doi.org/10.1126/scitranslmed.aaf1443
17. Holz FG, Sadda SR, Busbee B, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials. JAMA Ophthalmol 2018;136:666-77. DOI: https://doi.org/10.1001/jamaophthalmol.2018.1544
18. Heier JS, Pieramici D, Chakravarthy U, et al. Visual function decline resulting from geographic atrophy: results from the Chroma and Spectri phase 3 trials. Ophthalmol Retina 2020;4:673-88. DOI: https://doi.org/10.1016/j.oret.2020.01.019
19. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010;31:E1445-60. DOI: https://doi.org/10.1002/humu.21256
20. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology 2014;121:693-701. DOI: https://doi.org/10.1016/j.ophtha.2013.09.044
21. Li W, Chen S, Ma M, Qian J, Ma X. Complement 5b-9 complex-induced alterations in human RPE cell physiology. Med Sci Monit 2010;16:BR17-23.
22. Jaffe GJ, Westby K, Csaky KG, et al. C5 Inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. Ophthalmology 2021;128:576-86. DOI: https://doi.org/10.1016/j.ophtha.2020.08.027
23. Widmer RJ, Flammer AJ, Lerman LO, Lerman A. The Mediterranean diet, its components, and cardiovascular disease. Am J Med 2015;128:229-38. DOI: https://doi.org/10.1016/j.amjmed.2014.10.014
24. Dinu M, Pagliai G, Casini A, Sofi F. Mediterranean diet and multiple health outcomes: an umbrella review of meta-analyses of observational studies and randomised trials. Eur J Clin Nutr 2018;72:30-43. DOI: https://doi.org/10.1038/ejcn.2017.58
25. Keenan TD, Agron E, Mares J, et al. Adherence to the Mediterranean diet and progression to late age-related macular degeneration in the Age-Related Eye Disease Studies 1 and 2. Ophthalmology 2020;127:1515-28. DOI: https://doi.org/10.1016/j.ophtha.2020.04.030
26. Packer L, Roy S, Sen CK. Alpha-lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. Adv Pharmacol 1997;38:79-101. DOI: https://doi.org/10.1016/S1054-3589(08)60980-1
27. Liu J, Ames BN. Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease. Nutr Neurosci 2005;8:67-89. DOI: https://doi.org/10.1080/10284150500047161
28. Jia L, Liu Z, Sun L, et al. Acrolein, a toxicant in cigarette smoke, causes oxidative damage and mitochondrial dysfunction in RPE cells: protection by (R)-alpha-lipoic acid. Invest Ophthalmol Vis Sci 2007;48:339-48. DOI: https://doi.org/10.1167/iovs.06-0248
29. Sun YD, Dong YD, Fan R, Zhai LL, Bai YL, Jia LH. Effect of (R)-alpha-lipoic acid supplementation on serum lipids and antioxidative ability in patients with age-related macular degeneration. Ann Nutr Metab 2012;60:293-7. DOI: https://doi.org/10.1159/000338444
30. Kasahara E, Lin LR, Ho YS, Reddy VN. SOD2 protects against oxidation-induced apoptosis in mouse retinal pigment epithelium: implications for age-related macular degeneration. Invest Ophthalmol Vis Sci 2005;46:3426-34. DOI: https://doi.org/10.1167/iovs.05-0344
31. Cao J, Murat C, An W, et al. Human umbilical tissue-derived cells rescue retinal pigment epithelium dysfunction in retinal degeneration. Stem Cells 2016;34:367-79. DOI: https://doi.org/10.1002/stem.2239
32. Lund RD, Wang S, Lu B, et al. Cells isolated from umbilical cord tissue rescue photoreceptors and visual functions in a rodent model of retinal disease. Stem Cells 2007;25:602-11. DOI: https://doi.org/10.1634/stemcells.2006-0308erratum
33. Ho AC, Chang TS, Samuel M, Williamson P, Willenbucher RF, Malone T. Experience with a subretinal cell-based therapy in patients with geographic atrophy secondary to age-related macular degeneration. Am J Ophthalmol 2017;179:67-80. DOI: https://doi.org/10.1016/j.ajo.2017.04.006
34. Heier JS, Ho AC, Samuel MA, et al. Safety and efficacy of subretinally administered palucorcel for geographic atrophy of age-related macular degeneration: phase 2b study. Ophthalmol Retina 2020;4:384-93. DOI: https://doi.org/10.1016/j.oret.2019.11.011
35. Schwartz SD, Tan G, Hosseini H, Nagiel A. Subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium for the treatment of macular degeneration: an assessment at 4 years. Invest Ophthalmol Vis Sci 2016;57:ORSFc1-9. DOI: https://doi.org/10.1167/iovs.15-18681
36. Kashani AH, Uang J, Mert M, et al. Surgical method for implantation of a biosynthetic retinal pigment epithelium monolayer for geographic atrophy: experience from a phase 1/2a study. Ophthalmol Retina 2020;4:264-73. DOI: https://doi.org/10.1016/j.oret.2019.09.017
37. Petrukhin K. Pharmacological inhibition of lipofuscin accumulation in the retina as a therapeutic strategy for dry AMD treatment. Drug Discov Today Ther Strateg 2013;10:e11-e20. DOI: https://doi.org/10.1016/j.ddstr.2013.05.004
38. Rosenfeld PJ, Dugel PU, Holz FG, et al. Emixustat hydrochloride for geographic atrophy secondary to age-related macular degeneration: a randomized clinical trial. Ophthalmology 2018;125:1556-67. DOI: https://doi.org/10.1016/j.ophtha.2018.03.059
39. Lin J, Su Y, Wang C, et al. Effects of tandospirone augmentation in major depressive disorder patients with high anxiety: a multicenter, randomized, parallel-controlled, open-label study. J Psychiatr Res 2018;99:104-10. DOI: https://doi.org/10.1016/j.jpsychires.2018.01.020
40. Bode-Greuel KM, Klisch J, Horvath E, Glaser T, Traber J. Effects of 5-hydroxytryptamine1A-receptor agonists on hippocampal damage after transient forebrain ischemia in the Mongolian gerbil. Stroke 1990;21(12 Suppl):IV164-6.
41. Collier RJ, Patel Y, Martin EA, et al. Agonists at the serotonin receptor (5-HT1A) protect the retina from severe photo-oxidative stress. Invest Ophthalmol Vis Sci 2011;52:2118-26. DOI: https://doi.org/10.1167/iovs.10-6304
42. Jaffe GJ, Schmitz-Valckenberg S, Boyer D, et al. Randomized trial to evaluate tandospirone in geographic atrophy secondary to age-related macular degeneration: the GATE Study. Am J Ophthalmol 2015;160:1226-34. DOI: https://doi.org/10.1016/j.ajo.2015.08.024
43. Mody N, McIlroy GD. The mechanisms of Fenretinide-mediated anti-cancer activity and prevention of obesity and type-2 diabetes. Biochem Pharmacol 2014;91:277-86. DOI: https://doi.org/10.1016/j.bcp.2014.07.012
44. Sparrow JR, Zhou J, Ben-Shabat S, Vollmer H, Itagaki Y, Nakanishi K. Involvement of oxidative mechanisms in blue-light-induced damage to A2E-laden RPE. Invest Ophthalmol Vis Sci 2002;43:1222-7.
45. Mata NL, Lichter JB, Vogel R, Han Y, Bui TV, Singerman LJ. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina 2013;33:498-507. DOI: https://doi.org/10.1097/IAE.0b013e318265801d
46. Camardo J. The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation. Transplant Proc 2003;35(3 Suppl):18S-24S. DOI: https://doi.org/10.1016/S0041-1345(03)00356-7
47. Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother 2001;2:1903-17. DOI: https://doi.org/10.1517/14656566.2.11.1903
48. Agarwal A, Rajagopalan N, Hassan M, et al. Sirolimus for retinal and uveitic diseases. Dev Ophthalmol 2016;55:276-81. DOI: https://doi.org/10.1159/000438951
49. Petrou PA, Cunningham D, Shimel K, et al. Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci 2014;56:330-8. DOI: https://doi.org/10.1167/iovs.14-15877
50. Wong WT, Dresner S, Forooghian F, et al. Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci 2013;54:2941-50. DOI: https://doi.org/10.1167/iovs.13-11650
51. Fuhrmann S, Kirsch M, Hofmann HD. Ciliary neurotrophic factor promotes chick photoreceptor development in vitro. Development 1995;121:2695-706. DOI: https://doi.org/10.1242/dev.121.8.2695
52. Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A 2011;108:6241-5. DOI: https://doi.org/10.1073/pnas.1018987108
53. Marzilli M, Vinereanu D, Lopaschuk G, et al. Trimetazidine in cardiovascular medicine. Int J Cardiol 2019;293:39-44. DOI: https://doi.org/10.1016/j.ijcard.2019.05.063
54. Cohen SY, Bourgeois H, Corbe C, et al. Randomized clinical trial France DMLA2: effect of trimetazidine on exudative and nonexudative age-related macular degeneration. Retina 2012;32:834-43. DOI: https://doi.org/10.1097/IAE.0b013e31822058a3
55. Lusthaus JA, Goldberg I. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation. Expert Opin Drug Saf 2017;16:1071-8. DOI: https://doi.org/10.1080/14740338.2017.1346083
56. Ramírez C, Cáceres-del-Carpio J, Chu J, et al. Brimonidine can prevent in vitro hydroquinone damage on retinal pigment epithelium cells and retinal muller cells. J Ocul Pharmacol Ther 2016;32:102-8. DOI: https://doi.org/10.1089/jop.2015.0083
57. Kuppermann BD, Patel SS, Boyer DS, et al. Phase 2 study of the safety and efficacy of brimonidine drug delivery system (Brimo DDS) generation 1 in patients with geographic atrophy secondary to age-related macular degeneration. Retina 2021;41:144-55. DOI: https://doi.org/10.1097/IAE.0000000000002789
58. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12. DOI: https://doi.org/10.1001/jama.1995.03520290060030
59. Zhang J, Kiser PD, Badiee M, et al. Molecular pharmacodynamics of emixustat in protection against retinal degeneration. J Clin Invest 2015;125:2781-94. DOI: https://doi.org/10.1172/JCI80950
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Hong Kong Journal of Ophthalmology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Journal has a fully Open Access policy and publishes all articles under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. For any use other than that permitted by this license, written permission must be obtained from the Journal.
